Overview

Long-term Safety of SPD489 When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia

Status:
Terminated

Trial end date:
2013-04-01

Target enrollment:

Participant gender:

Summary

The primary purpose of this study is to determine if the long-term use of SPD489 (40, 80, 100, 120, 140, and 160mg) administered as a daily morning is safe and tolerable.

Phase:

Phase 3

Details

Lead Sponsor:

Shire

Treatments:

Antipsychotic Agents
Lisdexamfetamine Dimesylate